Isaralgagene Civaparvovec is a gene therapy commercialized by Sangamo Therapeutics, with a leading Phase II program in Fabry Disease. According to Globaldata, it is involved in 2 clinical trials, which are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Isaralgagene Civaparvovec’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Isaralgagene Civaparvovec is expected to reach an annual total of $138 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Isaralgagene Civaparvovec Overview
Isaralgagene civaparvovec (ST-920) is under development for the treatment of Fabry disease. The therapeutic candidate is a gene therapy that comprises recombinant adeno-associated virus vector serotype 2/6 (AAV2/6) encoding a human alpha-galactosidase A cDNA expressing galactosidase alpha (GLA) enzyme gene. It is formulated as solution and administered through intravenous route. It is developed based on the zinc finger protein (ZFP) Technology.
Sangamo Therapeutics Overview
Sangamo Therapeutics (Sangamo), formerly Sangamo BioSciences, is a biotechnology company that focuses on the research, development, and commercialization of engineered DNA-binding protein Zinc Finger Transcription (ZFPs). Its ZFPs candidates are based on its proprietary gene therapy technologies. It is advancing its pipeline candidates for the treatment of HIV/AIDS, hemophilia A and B, hurler syndrome (MPS I), Fabry disease, Huntington’s disease, Alzheimer’s disease, and many others. Its ZFPs based products are used in various applications such as human therapeutics, research reagents, pharmaceutical protein production, plant agriculture, cell-line engineering, and production of transgenic animals. Sangamo is headquartered in Brisbane, California, the US.
The company reported revenues of (US Dollars) US$110.7 million for the fiscal year ended December 2021 (FY2021), a decrease of 6.3% over FY2020. The operating loss of the company was US$183.3 million in FY2021, compared to an operating loss of US$129.6 million in FY2020. The net loss of the company was US$178.3 million in FY2021, compared to a net loss of US$121 million in FY2020.
The company reported revenues of US$26.5 million for the third quarter ended September 2022, a decrease of 9.9% over the previous quarter.
For a complete picture of Isaralgagene Civaparvovec’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.